Pulsesight reports positive phase 1 data for PST‑611 in dry AMD
Early safety and efficacy signals support move into repeat‑dose phase 2a trial
Read More
Author: John Pinching
UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
Partnership builds on existing collaboration and adds two new UCB‑nominated projects
Read More
Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage
Nihr‑funded phase 2 study to assess progesterone delivery using Callavid device
Read More
Virendra Shelar
Omron has appointed Virendra Shelar as CEO of Omron Europe
Read More
- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
